Anthem Blue Cross (HMO, PPO, EPO) |
Aimovig (erenumab-aooe) |
Drugs for the Nervous System : Drugs for Migraine Headaches |
- Migraine:
Duration: 3 Month(s)
Documented Diagnosis: Yes
Medical Test Required: No
Reauthorization Required: Yes
Duration of Reauthorization: = 1 year(s)
Migraine Frequency: 4 per month
Is supporting documentation required for initial approval: No
Is supporting documentation required for re-approval: No
Policy Contains Verbiage for Botulinum Interchangeability: No
Diagnosis of Chronic Migraine Required: No
Required Decrease in Duration of Chronic Migraine for Reauthorization: Unspecified
Provider Responsibility Language Referenced in Policy: No
Dose Conversion Language Included in Policy: No
Reauthorization Criteria Includes 50% Reduction Language: No
Reauthorization Criteria Includes 7 Day100 Hour Reduction Language: No
ICHD2ICHD3 Language Included in Policy: chronic migraines occurring at least 15 days in a single month, for at least 3 months
Retreatment Language Included in Policy: N/A
Policy Contains ICHD2 or ICHD3 Language: ICHD 3 criteria exist
Migraine Prevention: Duration: 3 Month(s)
Documented Diagnosis: Yes
- Prior Authorization: Migraine:
Documented Diagnosis: Yes
Duration: 3 Month(s)
Reauthorization Required: Yes
Migraine Prevention: Documented Diagnosis: Yes
Duration: 3 Month(s)
- Step Therapy: ST Multiple Generics
|